Drug Profile

Research programme: cell signalling inhibitors - Progenics

Latest Information Update: 19 Jun 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Progenics Pharmaceuticals
Class Small molecules
Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; ATP7A protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
06 Oct 2015 Discontinued - Preclinical for Cancer in USA (unspecified route) (Progenics pipeline, October 2015)
15 Mar 2013 Suspended - Preclinical for Cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com